Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM12WYV)

Drug Name
6-bromoindirubin-3-oxime Drug Info
Synonyms 6-bromoindirubin-3'-oxime (BIO)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
448949
ChEBI ID
CHEMBL355496
CAS Number
CAS 667463-62-9
TTD Drug ID
DM12WYV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glycogen synthase kinase-3 alpha (GSK-3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [6]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [7]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [8]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [7]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [7]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [7]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [7]
PMID27828716-Compound-21 DMO1NAR N. A. N. A. Patented [7]
Thiadiazolidindione derivative 2 DM5AUL0 N. A. N. A. Patented [7]
PMID27828716-Compound-18 DMNR6KL N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora B messenger RNA (AURKB mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [9]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [2]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [10]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [2]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [11]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [2]
CGP-57380 DMFPOUC Discovery agent N.A. Investigative [10]
PMID20855207C25 DMNEB6J Discovery agent N.A. Investigative [12]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [2]
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase A (AURKA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [14]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [15]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [16]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [18]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [16]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [19]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase C (AURKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [9]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [18]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
AMG 900 DMASGXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [22]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [23]
GSK1070916 DMXRPT6 Advanced solid tumour 2A00-2F9Z Phase 1 [24]
GSK1070916A DMCJUI9 Solid tumour/cancer 2A00-2F9Z Phase 1 [24]
MK-6592 DMB5NOI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [25]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [2]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [26]
Methotrexate DM2TEOL Anterior urethra cancer Approved [27]
Quercetin DM3NC4M Obesity 5B81 Approved [28]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [29]
Leflunomide DMR8ONJ Arthritis FA20 Approved [30]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [31]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [26]
Arsenic DMTL2Y1 N. A. N. A. Approved [33]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [35]
Quercetin DM3NC4M Obesity 5B81 Approved [3]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [36]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [37]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [38]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [39]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [40]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [41]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [44]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [45]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [46]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [47]
Cepharanthine DM9Y5JB N. A. N. A. Approved [48]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [49]
Clozapine DMFC71L Schizophrenia 6A20 Approved [50]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [51]
Trifluoperazine DMKBYWI Anxiety Approved [52]
Olanzapine DMPFN6Y Bipolar depression Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [53]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [55]
Quercetin DM3NC4M Obesity 5B81 Approved [56]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [57]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [58]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [59]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [60]
Testosterone DM7HUNW Hot flushes GA30 Approved [61]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [63]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [63]
Gefitinib DM15F0X Colon adenocarcinoma Approved [64]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [65]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [66]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [67]
Methotrexate DM2TEOL Anterior urethra cancer Approved [68]
Quercetin DM3NC4M Obesity 5B81 Approved [3]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [69]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [70]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora B messenger RNA (AURKB mRNA) TT9RTBL AURKB_HUMAN Inhibitor [2]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [2]
Aurora kinase C (AURKC) TTLYXIT AURKC_HUMAN Inhibitor [2]
Glycogen synthase kinase-3 alpha (GSK-3A) TTRZQE3 GSK3A_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Gene/Protein Processing [3]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [3]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [3]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Post-Translational Modifications [4]
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) OTMVHF9E LGR5_HUMAN Gene/Protein Processing [5]

References

1 Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis. 2009 Jun;47(6):414-22.
2 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
3 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
4 A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signaling. PLoS One. 2009 Sep 3;4(9):e6892. doi: 10.1371/journal.pone.0006892.
5 Analysis of glycogen synthase kinase inhibitors that regulate cytochrome P450 expression in primary human hepatocytes by activation of beta-catenin, aryl hydrocarbon receptor and pregnane X receptor signaling. Toxicol Sci. 2015 Nov;148(1):261-75.
6 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
7 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
8 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
9 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
10 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
11 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
12 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
13 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
14 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
15 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
16 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
17 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
18 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
19 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
21 Clinical pipeline report, company report or official report of Cyclacel.
22 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
23 SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
24 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
25 Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.
26 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
27 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
28 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
29 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
30 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
31 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
32 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
33 The aquaglyceroporin AQP9 contributes to the sex-specific effects of in utero arsenic exposure on placental gene expression. Environ Health. 2017 Jun 14;16(1):59. doi: 10.1186/s12940-017-0267-8.
34 Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
35 Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
36 ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
37 Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
38 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
39 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
40 Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
41 Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
42 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
43 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
44 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
45 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
46 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
47 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
48 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
49 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
50 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
51 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
52 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
53 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
54 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
55 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
56 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
57 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
58 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
59 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
60 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
61 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
62 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
63 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
64 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
65 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
66 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
67 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
68 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
69 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
70 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.